Efficacy of Ginkgo biloba in HCV-patients

Not Applicable

• Conditions: Nutritional, Metabolic, Endocrine; Hepatitis C

• Registration Number: PACTR201609001765772
• Lead Sponsor: Dina Mohamed kamal El-Gindy

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-09-05
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 67

Inclusion Criteria

positive serum anti-HCV Ab and HCV RNA
clinical and ultrasonographic criteria suggestive of chronic hepatitis C
Elevation of ALT at least 1.5 times the upper limit of normal (but < 5 times the normal limit)
Child Pugh Grade A

Exclusion Criteria

Child Pugh Grade was B or C
had other causes of liver disease or had evidence of advanced liver disease e.g. history or presence of ascitis, bleeding esophageal varices, or hepatic encephalopathy.
had portal vein thrombosis, hepatocellular carcinoma, seizure disorders
body mass index >40
advanced systemic disease like heart failure or any debilitating disease that will affect life expectancy
using oral contraceptive pills, selective serotonin reuptake inhibitors, narcotic drugs, blood thinning drugs or those who received a treatment of antiviral agents (interferon with or without ribavirin) in the previous 2 months.
pregnancy or lactation
patients with platelet level <50,000/µL patients with sensitivity to UDCA or EGb.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
liver enzymes;serum total antioxidant capacity;serum transforming growth factor beta1;serum Hyaluronic acid;International normalized Ratio (INR)

Secondary Outcome Measures

Name	Time	Method
adverse effects ;complete blood count